Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

Page 1 of 5

In this article, we discuss the top 5 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. If you want our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, go directly to the Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital.

5. Sutro Biopharma, Inc. (NASDAQ:STRO)

Samsara BioCapital’s Stake Value: $31.65 million

Percentage of Samsara BioCapital’s 13F Portfolio: 4.96%

Number of Hedge Fund Holders: 23

Sutro Biopharma, Inc. (NASDAQ:STRO), previously known as Fundamental Applied Biology, Inc., is a biopharmaceutical company driven on clinical-stage discovering, developing, and producing drugs. The company’s work focuses on cancer and autoimmune therapeutics. The firm is in a license agreement with Merck & Co Inc (NYSE:MRK) and Celgene Corporation.

On November 17, Berenberg analyst Zhiqiang Shu assumed the coverage of Sutro Biopharma, Inc. (NASDAQ:STRO) stock with a price target of $30.

According to the database of Insider Monkey that tracks 867 hedge funds, 23 funds held stakes in Sutro Biopharma, Inc. (NASDAQ:STRO) worth $213.8 million in the third quarter, down from 26 funds holding stakes worth $223.15 million in the previous quarter.

Page 1 of 5